688073.SH上海证券交易所 · 科创板 STAR
BIDE Pharmatech 毕得医药
Healthcare Services 医疗服务
¥73.91−¥0.64 · −0.86%
Open 开盘
¥75.78
High 最高
¥76.80
Low 最低
¥72.58
Prev Close 昨收
¥74.55
Volume 成交量
395.8万股
Turnover 成交额
¥2.93亿
Mkt Cap 总市值
¥67亿
P/E 市盈率
37.0×
Recent Activity 近期动态All Filings 全部公告 →
18 significant filings since 31 May 2026: 1 on change of control, 6 on equity incentive and 6 on change of interest, and 3 other kinds. The latest, on 28 Sep 2026: 国泰海通证券股份有限公司关于上海毕得医药科技股份有限公司首次公开发行股票募投项目结项并将节余募集资金及剩余超募资金永久补充流动资金的核查意见.
自 31 May 2026 起有 18 份重大公告：change of control 1 份、equity incentive 6 份、change of interest 6 份，另有 3 类。最新一份（28 Sep 2026）：国泰海通证券股份有限公司关于上海毕得医药科技股份有限公司首次公开发行股票募投项目结项并将节余募集资金及剩余超募资金永久补充流动资金的核查意见。
Price History 价格走势
1 session 个交易日, Mon 28 Sep 2026 · Live one-minute prices 实时分钟价格 · High 最高 ¥76.30 · Low 最低 ¥72.80 · −0.86% on the previous close of ¥74.55 较昨收73.0073.5074.0074.5075.0075.5076.00
Volume 成交量
29.5万
09:3010:3011:3014:0015:00
Overview 概览Deep Report 深度报告Financials 财务Valuation 估值Ownership 股东Analysts 券商Estimates 预测News 动态Events 事件Peers 同业
Relative Value 同业比较
Healthcare Services 医疗服务 · 54 listed peers
| Measure 指标 | This Company 本公司 | Peer Median 同业中值 | Standing 排位 | |
|---|---|---|---|---|
| Market Cap 市值 | ¥67亿 | ¥73亿 | 25th lowest of 54 · 54 家中第 25 低 | |
| Trailing P/E 市盈率 | 37.0x | 103.6x | 7th lowest of 38 · 38 家中第 7 低 | |
| P/B 市净率 | 3.3x | 3.4x | 27th lowest of 54 · 54 家中第 27 低 | |
| Revenue Growth 营收增速 | 8.8% | 4.0% | 22nd highest of 54 · 54 家中第 22 高 | |
| Profit Growth 净利增速 | 40.7% | 3.3% | 17th highest of 54 · 54 家中第 17 高 | |
| Gross Margin 毛利率 | 50.4% | 33.3% | 10th highest of 54 · 54 家中第 10 高 | |
| Net Margin 净利率 | 15.1% | 5.8% | 7th highest of 54 · 54 家中第 7 高 | |
| Return on Equity 净资产收益率 | 5.0% | 2.0% | 11th highest of 54 · 54 家中第 11 高 | |
| Debt to Assets 资产负债率 | 17.2% | 28.7% | 13th lowest of 54 · 54 家中第 13 低 | |
| Grade Score 评级得分 | 69 | 52 | 8th highest of 53 · 53 家中第 8 高 |
Statement figures are for the period to 30 Jun 2026, filed by 54 of 54 peers. A rank needs 5 or more peers with a value. A company with no earnings has no P/E. 报表数据为截至 30 Jun 2026 的期间，54 家同业中 54 家已披露。排位至少需要 5 家有数据的同业；无盈利的公司没有市盈率。
Largest Peers 主要同业
| Peer 同业 | Market Cap | P/E | P/B | Revenue Growth | Net Margin | ROE | Grade |
|---|---|---|---|---|---|---|---|
| Wuxi Apptec 药明康德 | ¥4,910亿 | 22.7x | 5.8x | 38.9% | 38.5% | 13.2% | B |
| Pharmaron Beijing 康龙化成 | ¥792亿 | 46.3x | 4.8x | 17.9% | 9.4% | 4.6% | C |
| Aier Eye Hospital Group 爱尔眼科 | ¥731亿 | 28.7x | 3.2x | 3.8% | 12.9% | 6.0% | C |
| Asymchem Laboratories 凯莱英 | ¥653亿 | 63.1x | 3.7x | 13.1% | 14.3% | 2.9% | C |
| Biocytogen 百奥赛图 | ¥568亿 | 155.2x | 23.5x | 51.6% | 25.6% | 10.5% | B |
| Hangzhou Tigermed Consulting 泰格医药 | ¥489亿 | 535.1x | 2.5x | 14.1% | -5.0% | -2.0% | D |
| Joinn 昭衍新药 | ¥340亿 | 34.6x | 3.8x | 5.3% | 106.2% | 8.6% | B |
| Haoyuan Chemexpress 皓元医药 | ¥214亿 | 82.7x | 6.7x | 25.7% | 9.8% | 5.3% | C |
| BGI Genomics 华大基因 | ¥187亿 | — | 2.2x | 9.6% | 2.7% | 0.6% | D |
| Hitgen 成都先导 | ¥175亿 | 124.9x | 11.5x | 52.4% | 23.0% | 5.2% | B |
| Meinian Onehealth Healthcare Holdings 美年健康 | ¥173亿 | 53.2x | 2.2x | -6.4% | -5.0% | -2.2% | E |
| Topchoice Medical 通策医疗 | ¥148亿 | 24.0x | 3.6x | 4.1% | 32.8% | 9.5% | C |
| Jiuzhou Pharma 九洲药业 | ¥145亿 | 24.5x | 1.6x | -10.3% | 14.8% | 4.3% | C |
| Gempharmatech 药康生物 | ¥144亿 | 78.8x | 6.3x | 22.6% | 24.1% | 4.8% | B |
| BIDE Pharmatech 毕得医药 | ¥67亿 | 37.0x | 3.3x | 8.8% | 15.1% | 5.0% | C |
Peers are listed by market cap, with this company highlighted. 同业按市值排列，本公司高亮显示。